Will Esperion Therapeutics (ESPR) Report Negative Earnings Next Week? What You Should Know

Core Viewpoint - Esperion Therapeutics (ESPR) is anticipated to report a year-over-year increase in earnings driven by higher revenues, with a consensus outlook suggesting a quarterly loss of $0.14 per share, reflecting a 72$70.01 million, marking a 117.1% increase from the same quarter last year [1][3]. Earnings Expectations - The upcoming earnings report is scheduled for March 4, and the stock may experience upward movement if the reported figures exceed expectations, while a miss could lead to a decline [2]. - The consensus EPS estimate has remained unchanged over the last 30 days, indicating stability in analyst expectations [4]. Earnings Surprise Prediction - The Zacks Earnings ESP model indicates that the Most Accurate Estimate for Esperion is lower than the Zacks Consensus Estimate, resulting in an Earnings ESP of -8.70%, suggesting a bearish outlook from analysts [10]. - The stock currently holds a Zacks Rank of 4, complicating predictions of an earnings beat [11]. Historical Performance - In the last reported quarter, Esperion was expected to post a loss of $0.14 per share but actually reported a loss of$0.15, resulting in a surprise of -7.14% [12]. - Over the past four quarters, the company has beaten consensus EPS estimates three times [13]. Industry Comparison - Amneal Pharmaceuticals (AMRX), another player in the Zacks Medical - Drugs industry, is expected to report earnings of $0.15 per share, reflecting a year-over-year change of +7.1$707.4 million, up 14.7% from the previous year [17]. - Amneal's consensus EPS estimate has remained unchanged, but a higher Most Accurate Estimate has resulted in an Earnings ESP of 2.27%, indicating a likelihood of beating the consensus EPS estimate [18].